Publication
Class III β-tubulin counteracts the ability of paclitaxel to inhibit cell migration.
Authors not recorded
Oncotarget2011PMID 21576762PMC3248193stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMalignant Neoplasmcivic_curation1.00
- drugPaclitaxelcivic_curation1.00
- geneTUBB3civic_curation1.00
- variantTUBB3 EXPRESSIONcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 21576762
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| TUBB3 EXPRESSION1 | ||||||||
| Paclitaxel | Malignant NeoplasmALIAS | Predictive | D | Supports Resistance | 2 | accepted | EID920High expression of class 3 beta-tubulin led to decreased effect of paclitaxel on cell motility in HeLa, MCF-7 and CHO cell lines. PMID 21576762 · Ganguly et al., 2011 · Open in CIViC | civic |